Clareo Health | Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Vertex Pharmaceuticals Incorporated
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Completed the final visit in the Treatment Period (i.e., Week 12) and subsequent 7-day period (to allow for taper of blinded capsule study drug) in a parent study such as VX24-548-110 or VX24-548-111
You may not be if
Any sensory abnormality (excluding DPN)
History of drug intolerance in a parent study that would pose an additional risk to the participant in the opinion of the investigator
Current participation in an investigational drug trial (other than a parent study)
